Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New insights into the pathogenesis and treatment of primary pulmonary hypertension.

Literature DB >> 11641516

New insights into the pathogenesis and treatment of primary pulmonary hypertension.

N Rudarakanchana¹, R C Trembath, N W Morrell.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2001 PMID： 11641516 PMCID： PMC1745964 DOI： 10.1136/thorax.56.11.888

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

× No keyword cloud information.

27 in total

1. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter.

Authors: W Ishida; T Hamamoto; K Kusanagi; K Yagi; M Kawabata; K Takehara; T K Sampath; M Kato; K Miyazono
Journal: J Biol Chem Date: 2000-03-03 Impact factor: 5.157

Review 2. TGF-beta signaling by Smad proteins.

Authors: K Miyazono
Journal: Cytokine Growth Factor Rev Date: 2000 Mar-Jun Impact factor: 7.638

Review 3. Controlling TGF-beta signaling.

Authors: J Massagué; Y G Chen
Journal: Genes Dev Date: 2000-03-15 Impact factor: 11.361

4. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling.

Authors: C Sirard; S Kim; C Mirtsos; P Tadich; P A Hoodless; A Itié; R Maxson; J L Wrana; T W Mak
Journal: J Biol Chem Date: 2000-01-21 Impact factor: 5.157

Review 5. Bone morphogenetic proteins: from basic studies to clinical approaches.

Authors: T Sakou
Journal: Bone Date: 1998-06 Impact factor: 4.398

6. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

Authors: S D Lee; K R Shroyer; N E Markham; C D Cool; N F Voelkel; R M Tuder
Journal: J Clin Invest Date: 1998-03-01 Impact factor: 14.808

7. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.

Authors: T Nakaoka; K Gonda; T Ogita; Y Otawara-Hamamoto; F Okabe; Y Kira; K Harii; K Miyazono; Y Takuwa; T Fujita
Journal: J Clin Invest Date: 1997-12-01 Impact factor: 14.808

8. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.

Authors: N W Morrell; X Yang; P D Upton; K B Jourdan; N Morgan; K K Sheares; R C Trembath
Journal: Circulation Date: 2001-08-14 Impact factor: 29.690

Review 9. Primary pulmonary hypertension.

Authors: S P Gaine; L J Rubin
Journal: Lancet Date: 1998-08-29 Impact factor: 79.321

New insights into the pathogenesis and treatment of primary pulmonary hypertension.

1. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter.

Review 2. TGF-beta signaling by Smad proteins.

Review 3. Controlling TGF-beta signaling.

4. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling.

Review 5. Bone morphogenetic proteins: from basic studies to clinical approaches.

6. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

7. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.

8. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.

Review 9. Primary pulmonary hypertension.

Review 10. Signal transduction by bone morphogenetic proteins.

1. The effect of rhBMP-2 on pulmonary arterioles remodeling in endotoxin-induced acute lung injury in rats.

2. Inhalation of Stachybotrys chartarum causes pulmonary arterial hypertension in mice.

3. PGC-1α induction in pulmonary arterial hypertension.

Review 4. Calcium channel blockers for pulmonary arterial hypertension.

5. Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension.